AstraZeneca’s AZD4604: Promising Results in Asthma Treatment Study

AstraZeneca (AZN) announced an update on their ongoing clinical study.

In a recent clinical study update, AstraZeneca has completed a Phase 2a study titled ‘A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA.’ The study aimed to assess the efficacy and safety of AZD4604, a new treatment for adults with moderate-to-severe asthma who do not respond well to existing therapies.

The intervention tested in this study was AZD4604, administered as a dry-powder inhaler. This drug is designed to improve asthma control in patients whose condition is not adequately managed with medium to high doses of inhaled corticosteroids and long-acting beta-agonists (ICS-LABA).

The study was interventional and involved random allocation of participants into two groups: one receiving AZD4604 and the other a placebo. It followed a parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors were all unaware of which treatment the participants received. The primary purpose of the study was treatment-focused.

The study began on August 25, 2023, with its primary completion and last update submitted on November 12, 2025. These dates are crucial as they mark the timeline of the study’s progress and the availability of its findings.

This update from AstraZeneca could influence the company’s stock performance positively, as successful results may enhance investor confidence and market position in the asthma treatment segment. Competitors in the respiratory treatment market may also be impacted as they adjust to potential new competition.

The study is now completed, with further details available on the ClinicalTrials portal.

To learn more about AZN’s potential, visit the AstraZeneca drug pipeline page.